{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:19:08Z","timestamp":1785529148858,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jiac.2024.102598","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T07:38:17Z","timestamp":1734766697000},"page":"102598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of ceftazidime-avibactam in combination with metronidazole in Japanese patients with complicated intra-abdominal infection: A phase 3, multicentre, open-label study"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8876-6411","authenticated-orcid":false,"given":"Hiroshige","family":"Mikamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiomi","family":"Nakazuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riko","family":"Tabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Tawadrous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Wible","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2024.102598_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13017-017-0141-6","article-title":"The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections","volume":"12","author":"Sartelli","year":"2017","journal-title":"World J Emerg Surg"},{"issue":"1","key":"10.1016\/j.jiac.2024.102598_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13017-021-00387-8","article-title":"WSES\/GAIS\/SIS-E\/WSIS\/AAST global clinical pathways for patients with intra-abdominal infections","volume":"16","author":"Sartelli","year":"2021","journal-title":"World J Emerg Surg"},{"issue":"1","key":"10.1016\/j.jiac.2024.102598_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40560-021-00555-7","article-title":"The Japanese clinical practice guidelines for management of sepsis and septic shock 2020 (J-sscg 2020)","volume":"9","author":"Egi","year":"2021","journal-title":"J Intensive Care"},{"issue":"1","key":"10.1016\/j.jiac.2024.102598_bib4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13017-024-00552-9","article-title":"Intra-abdominal infections survival guide: a position statement by the Global Alliance for Infections in Surgery","volume":"19","author":"Sartelli","year":"2024","journal-title":"World J Emerg Surg"},{"issue":"4","key":"10.1016\/j.jiac.2024.102598_bib5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.5603\/AIT.a2015.0026","article-title":"Management of abdominal sepsis--a paradigm shift?","volume":"47","author":"Leppaniemi","year":"2015","journal-title":"Anaesthesiol Intensive Ther"},{"issue":"1670","key":"10.1016\/j.jiac.2024.102598_bib6","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2014.0082","article-title":"Tackling the threat of antimicrobial resistance: from policy to sustainable action","volume":"370","author":"Shallcross","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"7","key":"10.1016\/j.jiac.2024.102598_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004264","article-title":"Antimicrobial resistance: addressing a global threat to humanity","volume":"20","author":"Walsh","year":"2023","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.jiac.2024.102598_bib8","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jiac.2021.12.033","article-title":"Epidemiology and molecular characterization of fecal carriage of third-generation cephalosporin-resistant Enterobacterales among elderly residents in Japan","volume":"28","author":"Nakai","year":"2022","journal-title":"J Infect Chemother"},{"issue":"1","key":"10.1016\/j.jiac.2024.102598_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40121-020-00395-2","article-title":"Continuous evolution: perspective on the epidemiology of carbapenemase resistance among Enterobacterales and other gram-negative bacteria","volume":"10","author":"Hansen","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"10","key":"10.1016\/j.jiac.2024.102598_bib10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/antibiotics10101189","article-title":"A view on 20 years of antimicrobial resistance in Japan by two national surveillance systems: the national epidemiological surveillance of infectious diseases and Japan nosocomial infections surveillance","volume":"10","author":"Suzuki","year":"2021","journal-title":"Antibiotics"},{"issue":"5","key":"10.1016\/j.jiac.2024.102598_bib11","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.jiac.2024.102598_bib12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.jiac.2024.102598_bib13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.jiac.2024.102598_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.jiac.2024.102598_bib15","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/jac\/dkad280","article-title":"Efficacy and safety of ceftazidime\/avibactam in patients with infections caused by \u03b2-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme","volume":"78","author":"Torres","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jiac.2024.102598_bib16","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s40121-021-00506-7","article-title":"Clinical and microbiological outcomes of ceftazidime-avibactam treatment in adults with gram-negative bacteremia: a subset analysis from the phase 3 clinical trial program","volume":"10","author":"Mazuski","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"9","key":"10.1016\/j.jiac.2024.102598_bib17","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1093\/jac\/dky204","article-title":"Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam Phase III clinical trial programme","volume":"73","author":"Stone","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.jiac.2024.102598_bib18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40264-020-00934-3","article-title":"Safety profile of ceftazidime-avibactam: pooled data from the adult phase II and phase III clinical trial programme","volume":"43","author":"Cheng","year":"2020","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.jiac.2024.102598_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02603-21","article-title":"Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant Enterobacterales bloodstream infection: a systematic review and meta-analysis","volume":"10","author":"Chen","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"4","key":"10.1016\/j.jiac.2024.102598_bib20","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","article-title":"Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review","volume":"10","author":"Soriano","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2024.102598_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis."},{"issue":"6","key":"10.1016\/j.jiac.2024.102598_bib22","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.21037\/jtd.2019.06.09","article-title":"Chinese guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults (2018 Edition)","volume":"11","author":"Shi","year":"2019","journal-title":"J Thorac Dis"},{"issue":"4","key":"10.1016\/j.jiac.2024.102598_bib23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.jiac.2024.102598_bib26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.12585","article-title":"Ceftazidime-avibactam population pharmacokinetic modeling and pharmacodynamic target attainment across adult indications and patient subgroups","volume":"12","author":"Li","year":"2019","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.jiac.2024.102598_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.jiac.2024.102598_bib28","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 34th Edition. https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/; 2022. [Accessed 4 July 2024]."},{"issue":"2","key":"10.1016\/j.jiac.2024.102598_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jiac.2018.10.012","article-title":"The efficacy and safety of tazobactam\/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections","volume":"25","author":"Mikamo","year":"2019","journal-title":"J Infect Chemother"},{"issue":"8","key":"10.1016\/j.jiac.2024.102598_bib32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jiac.2015.04.006","article-title":"Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers","volume":"21","author":"Tominaga","year":"2015","journal-title":"J Infect Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24003453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24003453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T17:01:49Z","timestamp":1741280509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24003453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1341321X24003453"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.102598","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of ceftazidime-avibactam in combination with metronidazole in Japanese patients with complicated intra-abdominal infection: A phase 3, multicentre, open-label study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.102598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102598"}}